Feeley Kevin 4

What Happened Kevin Feeley, Chief Financial Officer of GeneDx Holdings Corp. (WGS), had RSUs settle into common shares (3,815 shares on 2026-03-15 and 7,197 shares on 2026-03-16) at $0 per share and sold a portion in open-market transactions to cover tax withholding. He sold 2,384 shares at $76.35 ($182,016), 3,065 shares at $77.05 ($236,157), and 257 shares at $77.94 ($20,029), for total proceeds of approximately $438,202. The RSU settlement entries are reported as exercises/conversions of a derivative (code M) and the sales as open-market disposals (code S).

Key Details

• Transaction dates: RSU settlement/exercise 2026-03-15 and 2026-03-16; open-market sales on 2026-03-16. Form filed 2026-03-17.
• Shares acquired via settlement: 11,012 (3,815 + 7,197) at $0 per share. Shares sold: 5,706 total for ~$438,202.
• Sale price details: weighted-average prices reported; sold slices ranged ~ $75.735–$78.16 per share across transactions (see footnotes F3–F5 for ranges).
• Reason for sale: sell-to-cover tax withholding in connection with RSU vesting (footnote F2); not described as a discretionary investment sale.
• Holdings after transactions (footnote F6): 27,148 shares beneficially owned plus RSUs representing rights to up to 109,423 additional shares and options to purchase 25,906 shares.
• Vesting notes: portions of the awards vest annually/quarterly per footnotes F7 and F8.
• Filing timeliness: reported on 2026-03-17 for transactions on 3/15–3/16; no late filing indicated.

Context These transactions reflect routine “sell-to-cover” activity following RSU vesting (RSUs convert to shares for no cash cost, then some shares are sold to pay required tax withholding). Such tax-withholding sales are common and do not necessarily indicate a change in the insider’s view of the company. Feeley retained a meaningful position plus unvested RSUs/options after the transactions.